Hot Flash Remedies: Hormone-Free Treatments for Menopause
- What: The FDA recently approved two new non-hormonal medications - veozah (fezolinetant) and daybue (ospemifene) - to treat moderate to severe vasomotor symptoms (VMS) associated with...
- News originates from Brazil (Folha de S.Paulo) and reports are circulating globally.
- Why it Matters: these are the frist non-hormonal drugs specifically approved for treating hot flashes.
New Non-Hormonal Menopause Relief: A Fast Look
What: The FDA recently approved two new non-hormonal medications – veozah (fezolinetant) and daybue (ospemifene) – to treat moderate to severe vasomotor symptoms (VMS) associated with menopause, primarily hot flashes.
Where: United States (FDA approval). News originates from Brazil (Folha de S.Paulo) and reports are circulating globally.
When:
* Veozah approved May 11, 2023.
* Daybue approved Febuary 28, 2023.
* News coverage is current as of June 21, 2023.
Why it Matters: these are the frist non-hormonal drugs specifically approved for treating hot flashes. This offers a new option for the estimated 78% of women who experience these symptoms during menopause, particularly those who cannot or prefer not to use hormone therapy due to health concerns or personal preference. Hormone therapy remains the most effective treatment, but carries risks.
What’s Next:
* The medications are becoming available by prescription.
* Further research will likely focus on long-term effects and optimal use.
* Increased awareness and discussion among healthcare providers and patients.
Understanding the Medications
Here’s a breakdown of the two new drugs:
| Medication | Active Ingredient | Mechanism of Action | Common Side Effects (Reported in Trials) |
|---|---|---|---|
| Veozah | Fezolinetant | Neurokinin 3 (NK3) receptor antagonist - blocks a brain chemical involved in regulating body temperature. | Diarrhea, abdominal pain, nausea, insomnia. |
| Daybue | Ospemifene | Selective estrogen receptor modulator (SERM) – acts like a weak estrogen in some tissues, perhaps reducing hot flashes. | Vaginal discomfort, abnormal uterine bleeding, increased risk of stroke and blood clots (similar to, but potentially lower than, hormone therapy). |
Critically important Note: Side effects are based on clinical trial data and may not reflect the experience of all individuals. Consult with a healthcare professional for a complete list of potential risks and benefits.
Menopause & Hot Flashes: Key Statistics
* Prevalence: Approximately 78% of women experience hot flashes during menopause.
* Duration: Symptoms can last for an average of 7.4 years.
* Impact: Hot flashes can substantially disrupt sleep, daily activities, and overall quality of life.
* Hormone Therapy:** Remains the most effective treatment, but is not suitable for all women.
Custom Data Attributes (for potential future use/filtering):